AstraZeneca

AstraZeneca's IMFINZI® (durvalumab) approved by the FDA for treating limited-stage small cell lung cancer (LS-SCLC) after platinum-based chemotherapy and radiation therapy. The approval is based on the ADRIATIC Phase III trial results, showing improved survival rates and reduced risk of death and disease progression. IMFINZI is the first systemic treatment to demonstrate improved survival for LS-SCLC patients post-curative-intent chemoradiotherapy, with 57% of patients alive at three years. The drug also received approval in Switzerland and is under review in the EU, Japan, and other countries.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca is a leader in oncology, focusing on early detection and innovative treatments for lung cancer and immuno-oncology, aiming to redefine cancer care and eliminate it as a cause of death.

The precision medicine market is projected to grow by USD 66.2 billion from 2024-2028, driven by the rising prevalence of chronic diseases and the increasing use of AI and ML. However, data privacy and security issues pose challenges. Key players include AbbVie Inc., Amgen Inc., AstraZeneca Plc, and others.

Pharmaceutical and biotech companies often change names to reflect mission and focus. Notable changes include J&J renaming Janssen to Johnson & Johnson Innovative Medicine, BeiGene becoming BeOne Medicines, Vaccitech rebranding as Barinthus Biotherapeutics, Cullinan Oncology shifting to Cullinan Therapeutics, and Eliem Therapeutics renaming to Climb Bio.

FDA grants Merck's sacituzumab tirumotecan (sac-TMT) breakthrough therapy designation for advanced non-squamous NSCLC with EGFR mutations, post-chemotherapy progression. This marks the first BTD for sac-TMT, an ADC developed with Kelun-Biotech, with Merck holding global marketing rights except in Greater China.

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Novo Nordisk's CagriSema, combining semaglutide with cagrilintide, could be a breakthrough in obesity treatment. Analysts highlight amylin's role in satiety and hedonic eating, potentially improving weight reduction quality. Phase II results showed a 15.6% weight drop with CagriSema, and Phase III trials are ongoing. Competitors like Lilly and Zealand Pharma also advance amylin-based therapies, with promising early results.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.

Sarepta Therapeutics, known for its focus on Duchenne muscular dystrophy, made a $500 million upfront deal with Arrowhead Pharmaceuticals, investing $325 million and up to $10 billion in milestones. The deal aims to diversify Sarepta's pipeline with RNA drugs and expand its portfolio into new disease areas. Despite Elevidys failing a confirmatory trial, Sarepta secured full FDA approval and a label expansion, generating $181 million in Q3. The deal reflects Sarepta's ability to secure regulatory success and diversify its portfolio, potentially offering new options for patients with rare diseases.